- Home
- INSM vs FULTP Comparison
INSM vs FULTP Comparison
Compare INSM & FULTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- FULTP
- Stock Information
- Founded
- INSM 1988
- FULTP N/A
- Country
- INSM United States
- FULTP United States
- Employees
- INSM N/A
- FULTP 3400
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- FULTP Major Banks
- Sector
- INSM Health Care
- FULTP Finance
- Exchange
- INSM Nasdaq
- FULTP Nasdaq
- Market Cap
- INSM 13.7B
- FULTP N/A
- IPO Year
- INSM 2000
- FULTP N/A
- Fundamental
- Price
- INSM $81.01
- FULTP $19.54
- Analyst Decision
- INSM Strong Buy
- FULTP
- Analyst Count
- INSM 16
- FULTP 0
- Target Price
- INSM $84.29
- FULTP N/A
- AVG Volume (30 Days)
- INSM 2.0M
- FULTP N/A
- Earning Date
- INSM 02-20-2025
- FULTP N/A
- Dividend Yield
- INSM N/A
- FULTP N/A
- EPS Growth
- INSM N/A
- FULTP N/A
- EPS
- INSM N/A
- FULTP N/A
- Revenue
- INSM $342,958,000.00
- FULTP N/A
- Revenue This Year
- INSM $19.74
- FULTP N/A
- Revenue Next Year
- INSM $43.16
- FULTP N/A
- P/E Ratio
- INSM N/A
- FULTP N/A
- Revenue Growth
- INSM 22.13
- FULTP N/A
- 52 Week Low
- INSM $21.92
- FULTP N/A
- 52 Week High
- INSM $81.25
- FULTP N/A
- Technical
- Relative Strength Index (RSI)
- INSM 68.75
- FULTP 43.49
- Support Level
- INSM $74.47
- FULTP $19.22
- Resistance Level
- INSM $80.63
- FULTP $19.70
- Average True Range (ATR)
- INSM 2.98
- FULTP 0.36
- MACD
- INSM 0.55
- FULTP -0.01
- Stochastic Oscillator
- INSM 98.08
- FULTP 28.57
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About FULTP Fulton Financial Corporation Depositary Shares Each Representing a 1/40th Interest in a Share of Fixed Rate Non-Cumulative Perpetual Preferred Stock Series A
Fulton Financial is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey, and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.